Disease · MONDO_0020547
Trials81
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 81
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03112603 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | Phase 3 | 330 | 2022-04-15 | Graft-versus-host Disease (GVHD) | EVEROLIMUS, IBRUTINIB, IMATINIB, INFLIXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, PENTOSTATIN, RITUXIMAB, RUXOLITINIB, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT04710576 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | Phase 2 | 296 | 2024-10-10 | Chronic Graft-versus-host-disease | AXATILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02959944 | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) | Phase 3 | 193 | 2021-05-04 | Chronic Graft Versus Host Disease | IBRUTINIB, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT03640481 | Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy | Phase 2 | 159 | 2024-12-12 | Chronic Graft-versus-host-disease | BELUMOSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT03584516 | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Phase 2/3 | 155 | 2025-01-27 | Chronic Graft-versus-host Disease | ITACITINIB, METHYLPREDNISOLONE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00089141 | Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) | Phase 3 | 151 | 2009-08-26 | Cancer | MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT01309997 | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease | Phase 2 | 72 | 2016-06-15 | Graft Versus Host Disease, Systemic Scleroderma | IMATINIB MESYLATE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02701634 | Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) | Phase 2 | 66 | 2018-12-26 | Chronic Graft Versus Host Disease | ENTOSPLETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01380535 | Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) | Early phase 1 | 60 | 2019-10-29 | Chronic Graft Versus Host Disease | METHOXSALEN | Its record names the disease | ClinicalTrials.gov |
| NCT02513498 | Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease | Phase 2 | 50 | 2019-02-06 | Chronic Graft Versus Host Disease | IXAZOMIB CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT03616184 | Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids | Phase 2 | 49 | 2023-08-14 | Graft-versus-host-disease (GVHD) | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant | Phase 2 | 46 | 2025-04-17 | Graft vs Host Disease | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02195869 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease | Phase 1/2 | 45 | 2019-07-11 | Graft Versus Host Disease | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03604692 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | Phase 1/2 | 41 | 2024-11-27 | Chronic Graft-versus-host-disease | AXATILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00074035 | Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease | Phase 2 | 39 | 2017-03-15 | Graft Versus Host Disease | PENTOSTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04930562 | Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) | Phase 2 | 30 | 2023-11-01 | GVHD, Chronic | BELUMOSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT00656058 | Montelukast to Treat Bronchiolitis Obliterans | Phase 2 | 25 | 2016-10-21 | Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leukotriene, Montelukast, Stem Cell Transplant | MONTELUKAST | Its record names the disease | ClinicalTrials.gov |
| NCT02340676 | A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD | Phase 2 | 25 | 2018-10-18 | Chronic Graft-versus-host-disease | ALDESLEUKIN | Its record names the disease | ClinicalTrials.gov |
| NCT02759731 | Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1/2 | 24 | 2023-10-25 | Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05305989 | Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 | Phase 2 | 23 | 2025-05-02 | Chronic Graft-versus-host-disease | BELUMOSUDIL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020547/trials